Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: John McCarthy who wrote (21454)	5/27/1998 7:45:00 PM
From: Flagrante Delictu	Read Replies (2) \| Respond to of 32384

John, Sorry to hear about your misfortune with NPRO. Panretin gel would be the first topical treatment approved for KS, and shouldn't have to worry about Taxol therefore. However, it might be worth considering whether Panretin Oral could have a problem, if & when it gets approved. Maybe the 7 years will be up by then.

To: John McCarthy who wrote (21454)	6/1/1998 11:57:00 AM
From: StockDoc	Read Replies (2) \| Respond to of 32384

John McCarthy, I understand your frustration, this Orphan drug act can both help and kill others. This is the first thing a small pharmaceutical company should seek with the FDA when they start to develop a drug for a disease that affects less than 200,000 people annually. If they don't get it, it becomes more risky to develop the drug. If NPRO did not try to get orphan designation years ago when they started on KS, they're amateurs or incompetent. StockDoc